Contact
searchSearch
HMP Global
Login

Acute Myeloid Leukemia Specialty Channel

Acute Myeloid Leukemia
Specialty Channel
Quiz
Chidamide Plus Azacitidine Maintenance Therapy for AML
01/12/2026
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following...
01/12/2026
Oncology
News
Decitabine Plus Cedazuridine Maintenance Therapy Shows Promising Survival Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndromes
01/12/2026
Emily Estrada
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine...
01/12/2026
Oncology
News
Venetoclax Plus CACAG Regimen Demonstrates High Response Rates and Favorable Survival for R/R Acute Myeloid Leukemia
01/12/2026
Emily Estrada
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax...
01/12/2026
Oncology
Quiz
Enasidenib Plus Venetoclax for IDH2-Mutant AML
12/01/2025
True or False: According to results from the ENAVEN-AML trial, the combination of enasidenib and venetoclax showed encouraging clinical activity and a manageable safety profile among patients with R/R acute myeloid leukemia and an IDH2...
True or False: According to results from the ENAVEN-AML trial, the combination of enasidenib and venetoclax showed encouraging clinical activity and a manageable safety profile among patients with R/R acute myeloid leukemia and an IDH2...
True or False: According to...
12/01/2025
Oncology
News
Chidamide Plus Azacitidine Maintenance Demonstrates Promising Activity for Preventing Relapse After alloHSCT for Patients With High-Risk AML
12/01/2025
Emily Estrada
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and...
12/01/2025
Oncology
News
Autologous Stem Cell Transplantation Shows Improved Relapse-Free Survival Benefit Over Chemotherapy for AML Consolidation Therapy
12/01/2025
Emily Estrada
Among patients with acute myeloid leukemia in first remission, autoSCT showed significantly improved relapse-free and overall survival compared with chemotherapy according to a real-world, retrospective study.
Among patients with acute myeloid leukemia in first remission, autoSCT showed significantly improved relapse-free and overall survival compared with chemotherapy according to a real-world, retrospective study.
Among patients with acute...
12/01/2025
Oncology
FDA Approval
FDA Approves Ziftomenib for Patients With Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
11/13/2025
Emily Estrada
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a...
11/13/2025
Oncology
Quiz
Venetoclax Plus Azacitidine for Relapsed AML
10/30/2025
Emily Estrada
True or False: Venetoclax combined with azacitidine demonstrated poor clinical responses with unmanageable toxicity for elderly patients with relapsed acute myeloid leukemia, based on results from a single-center retrospective study.
True or False: Venetoclax combined with azacitidine demonstrated poor clinical responses with unmanageable toxicity for elderly patients with relapsed acute myeloid leukemia, based on results from a single-center retrospective study.
True or False: Venetoclax...
10/30/2025
Oncology
News
Enasidenib Plus Venetoclax Demonstrates Promising Activity for Relapsed/Refractory IDH2-Mutant AML: ENAVEN-AML Trial
10/30/2025
Emily Estrada
According to results from the ENAVEN-AML trial, enasidenib combined with venetoclax demonstrated clinical activity and manageable safety for R/R IDH2-mutated acute myeloid leukemia.
According to results from the ENAVEN-AML trial, enasidenib combined with venetoclax demonstrated clinical activity and manageable safety for R/R IDH2-mutated acute myeloid leukemia.
According to results from the...
10/30/2025
Oncology
FDA Approval
FDA Grants Approval to Revumenib for Patients With R/R NPM1-Mutated Acute Myeloid Leukemia
10/24/2025
Emily Estrada
The US Food and Drug Administration has approved revumenib for the treatment of relapsed/refractory acute myeloid leukemia for patients with an NPM1 mutation.
The US Food and Drug Administration has approved revumenib for the treatment of relapsed/refractory acute myeloid leukemia for patients with an NPM1 mutation.
The US Food and Drug...
10/24/2025
Oncology
Quiz
Survival Outcomes of Patients With AML and Concurrent DNMT3A & TET2 Mutations
10/02/2025
True or False: Patients with concurrent DNMT3A and TET2 mutations and acute myeloid leukemia demonstrated superior treatment responses and survival outcomes compared to patients without mutations, according to a retrospective analysis.
True or False: Patients with concurrent DNMT3A and TET2 mutations and acute myeloid leukemia demonstrated superior treatment responses and survival outcomes compared to patients without mutations, according to a retrospective analysis.
True or False: Patients with...
10/02/2025
Oncology

News

News
Decitabine Plus Cedazuridine Maintenance Therapy Shows Promising Survival Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndromes
01/12/2026
Emily Estrada
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine...
01/12/2026
Oncology
News
Venetoclax Plus CACAG Regimen Demonstrates High Response Rates and Favorable Survival for R/R Acute Myeloid Leukemia
01/12/2026
Emily Estrada
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax...
01/12/2026
Oncology
News
Chidamide Plus Azacitidine Maintenance Demonstrates Promising Activity for Preventing Relapse After alloHSCT for Patients With High-Risk AML
12/01/2025
Emily Estrada
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and...
12/01/2025
Oncology
News
Autologous Stem Cell Transplantation Shows Improved Relapse-Free Survival Benefit Over Chemotherapy for AML Consolidation Therapy
12/01/2025
Emily Estrada
Among patients with acute myeloid leukemia in first remission, autoSCT showed significantly improved relapse-free and overall survival compared with chemotherapy according to a real-world, retrospective study.
Among patients with acute myeloid leukemia in first remission, autoSCT showed significantly improved relapse-free and overall survival compared with chemotherapy according to a real-world, retrospective study.
Among patients with acute...
12/01/2025
Oncology
FDA Approval
FDA Approves Ziftomenib for Patients With Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
11/13/2025
Emily Estrada
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a...
11/13/2025
Oncology
News
Enasidenib Plus Venetoclax Demonstrates Promising Activity for Relapsed/Refractory IDH2-Mutant AML: ENAVEN-AML Trial
10/30/2025
Emily Estrada
According to results from the ENAVEN-AML trial, enasidenib combined with venetoclax demonstrated clinical activity and manageable safety for R/R IDH2-mutated acute myeloid leukemia.
According to results from the ENAVEN-AML trial, enasidenib combined with venetoclax demonstrated clinical activity and manageable safety for R/R IDH2-mutated acute myeloid leukemia.
According to results from the...
10/30/2025
Oncology
FDA Approval
FDA Grants Approval to Revumenib for Patients With R/R NPM1-Mutated Acute Myeloid Leukemia
10/24/2025
Emily Estrada
The US Food and Drug Administration has approved revumenib for the treatment of relapsed/refractory acute myeloid leukemia for patients with an NPM1 mutation.
The US Food and Drug Administration has approved revumenib for the treatment of relapsed/refractory acute myeloid leukemia for patients with an NPM1 mutation.
The US Food and Drug...
10/24/2025
Oncology
News
PD-1 Inhibitor Plus Azacitidine and HAG Regimen Demonstrates Promising Activity for R/R Acute Myeloid Leukemia
10/02/2025
Emily Estrada
According to a phase 2 trial, a PD-1 inhibitor combined with azacitidine and homoharringtonine, cytarabine, and G-CSF therapy demonstrated promising efficacy and safety among patients with relapsed/refractory acute myeloid leukemia.
According to a phase 2 trial, a PD-1 inhibitor combined with azacitidine and homoharringtonine, cytarabine, and G-CSF therapy demonstrated promising efficacy and safety among patients with relapsed/refractory acute myeloid leukemia.
According to a phase 2 trial, a...
10/02/2025
Oncology
News
Ruxolitinib and Decitabine With Modified Busulfan/Cyclophosphamide Conditioning Treatment Tolerable, Reduces Relapse for High-Risk AML/MDS
10/02/2025
Emily Estrada
Additional ruxolitinib to decitabine with modified busulfan/cyclophosphamide therapy, showed promising relapse reduction and tolerability for high-risk acute myeloid leukemia and myelodysplastic syndrome with increased blasts treatment.
Additional ruxolitinib to decitabine with modified busulfan/cyclophosphamide therapy, showed promising relapse reduction and tolerability for high-risk acute myeloid leukemia and myelodysplastic syndrome with increased blasts treatment.
Additional ruxolitinib to...
10/02/2025
Oncology
News
Venetoclax Plus Azacitidine Shows Promising Activity Among Elderly Patients With Relapsed AML
10/02/2025
Emily Estrada
For patients over the age of 65 years with relapsed acute myeloid leukemia, including those with adverse cytogenetic features, the combination of venetoclax and azacitidine demonstrated promising clinical activity and manageable safety.
For patients over the age of 65 years with relapsed acute myeloid leukemia, including those with adverse cytogenetic features, the combination of venetoclax and azacitidine demonstrated promising clinical activity and manageable safety.
For patients over the age of 65...
10/02/2025
Oncology

Interactive Features

Quiz
Chidamide Plus Azacitidine Maintenance Therapy for AML
01/12/2026
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following...
01/12/2026
Oncology
Quiz
Enasidenib Plus Venetoclax for IDH2-Mutant AML
12/01/2025
True or False: According to results from the ENAVEN-AML trial, the combination of enasidenib and venetoclax showed encouraging clinical activity and a manageable safety profile among patients with R/R acute myeloid leukemia and an IDH2...
True or False: According to results from the ENAVEN-AML trial, the combination of enasidenib and venetoclax showed encouraging clinical activity and a manageable safety profile among patients with R/R acute myeloid leukemia and an IDH2...
True or False: According to...
12/01/2025
Oncology
Quiz
Venetoclax Plus Azacitidine for Relapsed AML
10/30/2025
Emily Estrada
True or False: Venetoclax combined with azacitidine demonstrated poor clinical responses with unmanageable toxicity for elderly patients with relapsed acute myeloid leukemia, based on results from a single-center retrospective study.
True or False: Venetoclax combined with azacitidine demonstrated poor clinical responses with unmanageable toxicity for elderly patients with relapsed acute myeloid leukemia, based on results from a single-center retrospective study.
True or False: Venetoclax...
10/30/2025
Oncology
Quiz
Survival Outcomes of Patients With AML and Concurrent DNMT3A & TET2 Mutations
10/02/2025
True or False: Patients with concurrent DNMT3A and TET2 mutations and acute myeloid leukemia demonstrated superior treatment responses and survival outcomes compared to patients without mutations, according to a retrospective analysis.
True or False: Patients with concurrent DNMT3A and TET2 mutations and acute myeloid leukemia demonstrated superior treatment responses and survival outcomes compared to patients without mutations, according to a retrospective analysis.
True or False: Patients with...
10/02/2025
Oncology
Quiz
Venetoclax and CPX-531 for R/R AML
08/25/2025
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2...
08/25/2025
Oncology
Quiz
Ziftomenib Monotherapy for R/R NPM1-Mutant AML
08/13/2025
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to...
08/13/2025
Oncology
Quiz
Olutasidenib for R/R IDH1-Mutant AML
07/17/2025
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis...
07/17/2025
Oncology
Quiz
Tislelizumab Plus HMA and CAG for Relapsed/Refractory AML
06/16/2025
In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
In an expanded phase 2 trial...
06/16/2025
Oncology
Quiz
Combination Iadademstat and Azacitidine for Patients With Patients With Newly Diagnosed AML
09/25/2024
True or False: According to results from the phase 2a, dose-finding ALICE study, the frontline combination of iadademstat and azacitidine failed to produce promising responses among patients with newly diagnosed acute myeloid leukemia,...
True or False: According to results from the phase 2a, dose-finding ALICE study, the frontline combination of iadademstat and azacitidine failed to produce promising responses among patients with newly diagnosed acute myeloid leukemia,...
True or False: According to...
09/25/2024
Oncology
Quiz
Treating Acute Myeloid Leukemia With Aspacytarabine
03/05/2024
True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.
True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.
True or False: Aspacytarabine...
03/05/2024
Oncology

Recent Stories

Quiz
Chidamide Plus Azacitidine Maintenance Therapy for AML
01/12/2026
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following...
01/12/2026
Oncology
News
Decitabine Plus Cedazuridine Maintenance Therapy Shows Promising Survival Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndromes
01/12/2026
Emily Estrada
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine...
01/12/2026
Oncology
News
Venetoclax Plus CACAG Regimen Demonstrates High Response Rates and Favorable Survival for R/R Acute Myeloid Leukemia
01/12/2026
Emily Estrada
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax...
01/12/2026
Oncology
Quiz
Enasidenib Plus Venetoclax for IDH2-Mutant AML
12/01/2025
True or False: According to results from the ENAVEN-AML trial, the combination of enasidenib and venetoclax showed encouraging clinical activity and a manageable safety profile among patients with R/R acute myeloid leukemia and an IDH2...
True or False: According to results from the ENAVEN-AML trial, the combination of enasidenib and venetoclax showed encouraging clinical activity and a manageable safety profile among patients with R/R acute myeloid leukemia and an IDH2...
True or False: According to...
12/01/2025
Oncology
News
Chidamide Plus Azacitidine Maintenance Demonstrates Promising Activity for Preventing Relapse After alloHSCT for Patients With High-Risk AML
12/01/2025
Emily Estrada
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and...
12/01/2025
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use